Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Proleukin cleared for marketing in U.S. for melanoma indication

Jan. 30, 1998

AltaRex reacquires Western European marketing rights to Ovarex

Jan. 27, 1998

New approach to cancer therapy reported

Jan. 27, 1998

Vical receives patent protection for lipid-mediated DNA vaccines

Jan. 8, 1998

Mechanism of TNF-alpha production in tumor tissues by Ono-4007

Jan. 5, 1998

Favorable phase III trial results reported for HER2 monoclonal antibody

Dec. 31, 1997

Chiron's Proleukin recommended for approval for new indication

Dec. 23, 1997

New antitumor agent in development in China

Dec. 22, 1997

Idec's immunotherapy shows promise in phase I/II for non-Hodgkin's lymphoma

Dec. 22, 1997

MAb for non-Hodgkin's lymphoma now available in U.S.

Dec. 19, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...